DNAJC1

DNAJC1 (MTJ1/ERdj1) is a transmembrane ER-resident co-chaperone of the Hsp40/J-protein family that couples the chaperone machinery to BiP/GRP78-dependent proteostasis and to cell-surface GRP78 signaling (PMID:10777498, PMID:15699139). Its topology places a J domain in the ER lumen flanked by transmembrane segments, with a cytosolic SANT-domain region (PMID:7875597). Through the lumenal J domain, DNAJC1 binds BiP/GRP78 and stimulates its ATPase activity stoichiometrically; this depends on the conserved HPD motif (H89Q abolishes both binding and stimulation) and engages the ATPase/substrate-binding core rather than the BiP C-terminal tail (PMID:10777498, PMID:11388813). The second SANT domain (SANT2) mediates high-affinity, sequence-specific protein interactions with serpins and related substrates, binding alpha1-antichymotrypsin (~0.5 nM, via tryptophans W497/W520) and the C-terminal fragment of ITIH4, in each case modulating proteolytic processing or inhibitory kinetics of the bound partner (PMID:14668352, PMID:16271702). Beyond the ER, DNAJC1 acts as an obligate anchor for translocation of GRP78 to the plasma membrane, where it is required for cell-surface GRP78 display, alpha2-macroglobulin binding, and downstream calcium signaling, assembling ternary signaling complexes with GRP78 and Galphaq11 (PMID:15699139, PMID:18213612). At the cell surface DNAJC1/GRP78 complexes also engage vaspin to drive Akt and AMPK phosphorylation (PMID:22837305). Within the ER proteostasis network, DNAJC1 has a specific, non-redundant role: its CRISPR knockout produces a distinct anticancer drug-resistance signature relative to other ERdj paralogs (PMID:35129801).

1. 1995 Medium

   Established DNAJC1 as a J-domain protein with a distinctive membrane topology, framing it as a SEC63-like ER/membrane co-chaperone rather than a soluble Hsp40.

   Evidence cDNA cloning, subcellular fractionation and immunodetection in murine tumor cells

   PMID:7875597

   Open questions at the time

   • Did not define the chaperone partner or catalytic activity
   • Precise membrane orientation of domains not resolved biochemically
2. 2000 High

   Defined the core catalytic mechanism by showing the lumenal J domain directly stimulates BiP/GRP78 ATPase activity through the HPD motif, establishing DNAJC1 as a bona fide BiP co-chaperone.

   Evidence In vitro ATPase assays with HPD-motif (H89Q) mutagenesis and biochemical interaction studies

   PMID:10777498

   Open questions at the time

   • Did not identify physiological substrates handed to BiP
   • Cellular consequences of ATPase stimulation not tested
3. 2001 Medium

   Localized the J-domain/BiP interaction to BiP's ATPase/substrate-binding core, ruling out the C-terminal domain as the contact surface.

   Evidence In vitro interaction assays with BiP deletion mutants

   PMID:11388813

   Open questions at the time

   • Structural details of the interface unresolved
   • Single-lab in vitro confirmation
4. 2001 Low

   Probed the function of the cytosolic SANT region, proposing a transcription-factor-like DNA-binding role based on nuclear relocalization upon transmembrane deletion.

   Evidence Computational prediction with transmembrane-deletion localization constructs

   PMID:11790253

   Open questions at the time

   • No direct DNA binding demonstrated
   • Relocalization may be an artifact of construct mislocalization
   • Endogenous nuclear function not established
5. 2003 High

   Assigned a high-affinity, sequence-specific binding function to the SANT2 domain by showing nanomolar binding to alpha1-antichymotrypsin and kinetic modulation of its protease-inhibitory activity.

   Evidence Yeast two-hybrid, native electrophoresis, fluorescence and kinetic enzyme assays with W497A/W520A mutagenesis

   PMID:14668352

   Open questions at the time

   • Physiological compartment of the ACT interaction unclear
   • Biological consequence of delayed serpin inhibition in cells not shown
6. 2005 High

   Revealed a cell-surface role: DNAJC1 is required to translocate GRP78 to the plasma membrane and to enable alpha2-macroglobulin binding and calcium signaling, extending its function beyond the ER lumen.

   Evidence siRNA silencing, plasma-membrane Co-IP, ligand binding and calcium signaling assays in macrophages

   PMID:15699139

   Open questions at the time

   • Mechanism of GRP78/DNAJC1 trafficking to the surface unknown
   • How a transmembrane ER protein reaches the plasma membrane not resolved
7. 2005 Medium

   Broadened SANT2 substrate scope to ITIH4 and showed protease-protection function, reinforcing SANT2 as a regulator of secreted serpin/inhibitor processing.

   Evidence Yeast two-hybrid, Co-IP from liver extracts, in vitro kallikrein protection assay

   PMID:16271702

   Open questions at the time

   • In vivo relevance of ITIH4 protection not established
   • Single-lab finding
8. 2008 Medium

   Defined the surface signaling architecture as a ternary GRP78/DNAJC1/Galphaq11 complex, both chaperone components being required for G-protein recruitment.

   Evidence Plasma-membrane Co-IP with dsRNA silencing of MTJ1 or GRP78 in stimulated macrophages

   PMID:18213612

   Open questions at the time

   • Direct vs indirect contact with Galphaq11 not distinguished
   • Downstream signaling steps not mapped
9. 2011 Low

   Extended the surface complex to additional partners (TFII-I, PLCgamma1, TRPC3, caveolin) and linked DNAJC1 to TFII-I surface display in prostate cancer cells.

   Evidence Plasma-membrane Co-IP and RNAi knockdown with surface-expression readout

   PMID:21503958

   Open questions at the time

   • Single Co-IP without reciprocal validation
   • Direct partners within the multimeric complex undefined
   • Functional consequence beyond TFII-I surface localization unclear
10. 2012 Medium

    Connected the surface GRP78/DNAJC1 complex to metabolic signaling by showing it mediates vaspin-induced Akt and AMPK phosphorylation.

    Evidence Tandem affinity purification, surface biotinylation, Co-IP from liver tissue, phosphorylation assays

    PMID:22837305

    Open questions at the time

    • Stoichiometry and direct vaspin contact not defined
    • In vivo metabolic outcome not tested
11. 2022 Medium

    Demonstrated a non-redundant role for DNAJC1 in ER proteostasis by showing CRISPR knockout yields a paralog-distinct anticancer drug-resistance signature.

    Evidence CRISPR KO chemogenomic screening across multiple cancer cell lines

    PMID:35129801

    Open questions at the time

    • Substrates underlying the drug-resistance phenotype unknown
    • Whether the effect requires J-domain or SANT2 activity untested
12. 2024 Medium

    Tested DNAJC1 in protein-aggregate handling, showing it assists GRP78 in remodeling PrPD aggregates to increase protease susceptibility rather than fully disaggregating them.

    Evidence Cell-free reconstituted chaperone assay (GRP78, DnaJC1, Stip1, Hsp90) with protease-sensitivity readout

    PMID:38718859

    Open questions at the time

    • Physiological relevance to prion clearance in cells unknown
    • Contribution of individual chaperone components not dissected
13. 2025 Low

    Placed DNAJC1 upstream in a beta-cell cytoprotective pathway, with its upregulation required for plantamajoside-mediated suppression of ER stress and apoptosis.

    Evidence siRNA knockdown in MIN6 cells with ER-stress/apoptosis marker Western blots and transcriptomics

    PMID:39959264

    Open questions at the time

    • No direct biochemical mechanism established
    • Correlative pathway placement without molecular target
    • Single-lab finding

• How DNAJC1 is trafficked from the ER membrane to the plasma membrane, and the structural basis by which its J domain and SANT2 modules coordinate ER proteostasis versus surface signaling, remain unresolved.
• No structural model of the full-length transmembrane protein
• Trafficking route to the cell surface unknown
• Endogenous ER substrate repertoire undefined